期刊文献+

厄贝沙坦对慢性心力衰竭和心肌纤维化的影响研究 被引量:5

The impact of Irbesartan in chronic heart failure and myocardial fibrosis
下载PDF
导出
摘要 目的 探讨厄贝沙坦对心力衰竭患者心功能和心肌纤维化的影响.方法 选择心力衰竭患者(NYHA分级为Ⅱ~Ⅳ级)100例,随机分为常规治疗组和厄贝沙坦组.每组50例;在治疗前和治疗后12周应用心脏彩色超声测定心功能变化(测量LVEF),采用放射免疫法检测血浆脑钠肽(BNP)、血清Ⅲ型前胶原氨基末端肽(PⅢNP)和透明质酸(HA)的浓度.结果 ①厄贝沙坦组BNP、PⅢNP和HA治疗后比常规治疗组治疗后降低效果更明显(P<0.05);两组患者LVEF值治疗后比治疗前明显升高(P<0.01),而且厄贝沙坦组治疗后与常规治疗组治疗后相比升高明显(P<0.05).②血清PⅢNP、HA与BNP值呈正相关,血清PⅢNP、HA与LVEF值呈负相关.结论 在常规治疗慢性心衰的基础上加用厄贝沙坦更能有效地抑制心脏HA和Ⅲ型胶原的产生,可以起到抗心肌纤维化、改善心功能的作用. Objective To investigate the effects of irbesartan in patients with heart failure on cardiac function and myocardial fibrosis. Methods 100 patients with heart failure (NYHA classification was grade Ⅱ- Ⅳ ) were randomly divided into conventional treatment group and irbesartan group (n=50). Cardiac function (LVEF) was determined by echocardiogram before and after 12 weeks treatment. Concentrations of brain natriuretic peptide (BNP), serum amino-terminal procollagen m peptide (PⅢNP) and hyaluronic acid (HA) were measured by radioimmunoassay. Results (1)In Irbesartan group, the levels of BNP, P Ⅲ NP and HA were significantly decreased than the conventional treatment group(P〈0.05 ), LVEF values of two groups were significantly improved af- ter treatment (P〈0.01), and improvement degree was significant in irbesartan group (P〈0.05). (2)Serum PⅢNP and HA were positively associated with the BNP, serum PⅢNP and HA was negatively associated with LVEF. Conclusion The conventional treatment of chronic heart failure based on the use of irbesartan inhibited the heart of HA and collagen m production more effectively, and may inhibit the myocardial fibrosis and improve cardiac function.
出处 《中国心血管病研究》 CAS 2011年第2期112-115,共4页 Chinese Journal of Cardiovascular Research
关键词 心力衰竭 厄贝沙坦 心肌纤维化 血浆脑钠肽 血清Ⅲ型前胶原氨基末端肽 透明质酸 Heart failure Irbesartan Myocardial fibrosis BNP PⅢNP HA
  • 相关文献

参考文献16

  • 1Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med, 2008,359 : 2456-2467.
  • 2王知军,张立功.充血性心力衰竭的现代研究新进展[J].中国心血管病研究,2006,4(9):708-710. 被引量:19
  • 3Gradman AH,Alfayoumi F. From left ventrieular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovase Dis, 2006,48 : 326-341.
  • 4Plaksej R, Kosmala W, Frantz S, et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. Hyper- tens, 2009,27 : 2483-2491.
  • 5Biolo A, Rohde LE, Goldraich LA, et al. Serum procollagen type I!I is associated with elevated right-sided filling pressures in sta- ble outpatients with congestive heart failure. Biomarkers,2009, 14 : 438-442.
  • 6Radauceanu A,Ducki C,Virion JM,et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail, 2008,14 : 467-474.
  • 7Fairweather D,Frisancho Kiss S,Yusung SA,et al. Interferon- gamma protects against chronic viralmyocarditisby reducingmast cellderegulation, fibrosis, and the profibrotic cytokines trans- forming growth factor-beta 1, interleukin-1 beta, and inter- leukin-4 in the heart. Am J Pathol,2004,165:1883-1894.
  • 8Klotz S, Danser AH, Foronjy RF, et al. The impact of angiotensin- converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assistdevice support in patients with end-stage heart failure. J Am Coil Cardiol, 2007,49 : 1166-1174.
  • 9Vanderheyden M,Vrints C, Verstreken S,et al. B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications.Biomark Med, 2010,4 : 315-320.
  • 10Ritchie RH,Rosenkranz AC,Kaye DM. B-type natriureticpeptide: endogenous regulator of myocardial structure, biomarker and therapeutic target. Curr Mol Med, 2009,9: 814-825.

二级参考文献23

共引文献24

同被引文献69

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部